Better Buy: Novavax vs. Vaxart

Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) are both biotechs which rose to prominence as a result of their efforts to develop and commercialize a coronavirus vaccine. Only Novavax has largely accomplished that goal so far, though its product isn't yet approved for sale in the U.S. But do its recent successes make it a better buy? The argument for buying Novavax is that in the near term it'll be raking in global sales of its coronavirus vaccine, which will continue to get approved for use in more and more jurisdictions.